» Articles » PMID: 2417962

Loss of HLA-A,B,C and De Novo Expression of HLA-D in Colorectal Cancer

Overview
Journal Int J Cancer
Specialty Oncology
Date 1986 Feb 15
PMID 2417962
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

One hundred primary colorectal carcinomas and 19 metastases were studied for the expression of HLA-A,B,C and HLA-D antigens using monoclonal antibodies (MAbs) against framework determinants and a sensitive immunoperoxidase technique on frozen sections. With MAb W6/32, 65 tumors were intensely stained for HLA-A,B,C; 22 showed a reduced staining intensity, in 5 carcinomas a minor or major subset of the tumor cells lacked HLA-A,B,C, and in 8 cases all tumor cells were unreactive. The loss of HLA-A,B,C was inversely correlated with the degree of differentiation. No relation was found to type, stage and site of the tumor, or to age and sex of the patients. With MAb 2.06, 58 tumors were HLA-D negative, 20 exhibited small positive foci, 19 showed a patchy staining pattern, and 3 were homogeneously HLA-D positive. There was no apparent correlation between HLA-D expression and any of the clinico-pathological features mentioned, nor was it related to the loss of HLA-A,B,C. About half of the metastases displayed the same staining pattern for HLA-A,B,C and -D as the respective primary tumors. The remainder differed from the primary carcinoma by gain or loss of HLA antigens.

Citing Articles

MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.

Puttick C, Jones T, Leung M, Galvez-Cancino F, Liu J, Varas-Godoy M Nat Genet. 2024; 56(10):2121-2131.

PMID: 39358601 PMC: 11525181. DOI: 10.1038/s41588-024-01883-8.


Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer.

Koukourakis I, Xanthopoulou E, Sgouras T, Kouroupi M, Giatromanolaki A, Kouloulias V Br J Cancer. 2023; 129(11):1852-1862.

PMID: 37838813 PMC: 10667544. DOI: 10.1038/s41416-023-02459-9.


Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review.

Koukourakis I, Platoni K, Tiniakos D, Kouloulias V, Zygogianni A Curr Issues Mol Biol. 2023; 45(5):4495-4517.

PMID: 37232754 PMC: 10216994. DOI: 10.3390/cimb45050285.


Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers.

Bolzacchini E, Libera L, Church S, Sahnane N, Bombelli R, Digiacomo N Cancers (Basel). 2022; 14(16).

PMID: 36010943 PMC: 9405961. DOI: 10.3390/cancers14163951.


Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Dhatchinamoorthy K, Colbert J, Rock K Front Immunol. 2021; 12:636568.

PMID: 33767702 PMC: 7986854. DOI: 10.3389/fimmu.2021.636568.